, Volume 37, Issue 3, pp 313-320

First online:

Expression of glomerular extracellular matrix components in human diabetic nephropathy: decrease of heparan sulphate in the glomerular basement membrane

  • J. T. TamsmaAffiliated withDepartment of Pathology, University Hospital Leiden
  • , J. van den BornAffiliated withDepartment of Nephrology, University Hospital Nijmegen
  • , J. A. BruijnAffiliated withDepartment of Pathology, University Hospital Leiden
  • , K. J. M. AssmannAffiliated withDepartment of Pathology, University Hospital Nijmegen
  • , J. J. WeeningAffiliated withDepartment of Pathology, University of GroningenDepartment of Pathology, University of Amsterdam
  • , J. H. M. BerdenAffiliated withDepartment of Nephrology, University Hospital Nijmegen
  • , J. WieslanderAffiliated withDepartment of Autoimmune Serology, Statens Seruminstitut
  • , E. SchramaAffiliated withDepartment of Nephrology, University Hospital Leiden
  • , J. HermansAffiliated withDepartment of Medical Statistics, University of Leiden
    • , J. H. VeerkampAffiliated withDepartment of Biochemistry, University of Nijmegen
    • , H. H. P. J. LemkesAffiliated withDepartment of Pathology, University Hospital Leiden
    • , F. J. van der WoudeAffiliated withDepartment of Pathology, University Hospital Leiden

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Diabetic nephropathy is characterized by albuminuria which proceeds to overt proteinuria. The highly negatively stained HS side chain of heparan sulphate proteoglycan (HSPG) is a major determinant of the charge-dependent permeability of the GBM. We set out to study the presence of HS and HSPG in the GBM of patients with diabetic nephropathy using newly developed monoclonal antibodies, and to compare HSPG expression to the expression of other previously investigated glomerular extracellular matrix compounds. Immunohistochemically, glomerular extracellular matrix components were analysed in 14 renal biopsies of patients with diabetic nephropathy and compared with those of normal control subjects. Monoclonal antibodies used were: JM403 against the HS side chain of GBM HSPG and JM72 against the HSPG-core protein. Also, a polyclonal antiserum (B31) against human GBM-HSPG-core protein was used. Additionally, antibodies were used against collagen types I, III, IV and against α1(IV)NC, α3(IV)NC and fibronectin. Staining was scored for intensity and for staining pattern by four independent observers who had no previous knowledge of the sample origin. No glomerular staining was seen for collagen type I. Collagen type III was present in some diabetic nodules. Anti-collagen type IV showed a decreased GBM staining in patients with diabetic nephropathy (p = 0.04). With anti-α1(IV)NC no changes in GBM staining intensity were observed; with anti-α3(IV)NC brilliant GBM staining was seen in both groups. Increased mesangial staining (p = 0.003) was seen with anti-collagen type IV in biopsies with nodular lesions. No differences were observed for fibronectin although it was abundantly present in the mesangial area of biopsies from patients with diabetic nephropathy. In biopsies with mesangial expansion and in biopsies with diabetic nodules, we observed a decreased GBM (p = 0.001) HS side chain staining (JM403) without changes in HSPG-core protein staining (JM72,B31). The HS staining pattern regularly changed from a linear to a more granular and irregular pattern. In patients with a creatinine clearance of more than 15 ml/min, the intensity of GBM HS staining showed an inverse correlation with the rate of proteinuria (r = -0.85, p = 0.004), suggesting a functional relationship. The decreased HS staining in the GBM may reflect the potentially disrupted charge barrier in diabetic nephropathy.

Key words

Diabetic nephropathy heparan sulphate heparan sulphate proteoglycan glomerular basement membrane extracellular matrix